A Phase 1b, Open-Label, Multiple-Dose Study Evaluating Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Pociredir in Patients with Sickle Cell Disease (SCD): Trial Design

Presenting Author(s)

• 

  Sheinei Alan, MD, PhD

  Sickle Cell Specialist
  Inova Adult Sickle Cell Program, Inova Schar Cancer Institute
  University of Virginia, School of Medicine Inova Campus
  Falls Church, Virginia, United States

  Slides

Co-Author(s)

• JM

  Johnny Mahlangu, BSc, MBBCh, MMed, FCPath

  N/A
  University of the Witwatersrand and NHLS
  Johannesburg, Gauteng, South Africa
• MB

  Michael Birrer, MD, PhD

  N/A
  University of Arkansas for Medical Sciences, Arkansas, United States
• FF

  Foluke Fasola, MD, FWACP

  N/A
  University of Ibadan/ University College Hospital
  Ibadan, Oyo, Nigeria
• BO

  Blessing Ojika, MBBS, FMCpath

  N/A
  National Hospital Abuja
  Abuja, Federal Capital Territory, Nigeria
• LD

  Livingstone Dogara, MBBS, FMCpath

  N/A
  Barau Dikko Teaching Hospital (BDTH) - Kaduna State University (KASU),
  Kaduna, Kaduna, Nigeria
• 

  Kenneth Rivlin, MD, PhD

  Chief, Division of Hematology/Oncology
  New York Health and Hospitals/Jacobi
  Albert Einstein College of Medicine
  Bronx, New York, United States
• CC

  Christy M. Copeland, PharmD

  Senior Director, Medical Affairs
  Fulcrum Therapeutics
  Cambridge, Massachusetts, United States
• RL

  Rita Lemming, BS

  Director, Clinical Operations
  Fulcrum Therapeutics
  Cambridge, Massachusetts, United States
• TW

  Thomas Winkler, MD

  VP, Clinical Development
  Fulcrum Therapeutics
  Cambridge, Massachusetts, United States
• 

  Caterina Minniti, MD

  N/A
  Albert Einstein College of Medicine
  Bronx, New York, United States